Menu
Menu
Question:
What OPPS billing guidelines should be followed when commercially available products are mixed together to facilitate their concurrent administration?
Answer:
Under the outpatient prospective payment system (OPPS), if commercially available products are being mixed together to facilitate their concurrent administration, the hospital should report (by HCPCS code) the quantity of each product used in the patient’s care. Alternatively, if the hospital is compounding drugs that are not a mixture of commercially available products, but are a different product that has no applicable HCPCS code, then the hospital should report an appropriate unlisted drug code (J9999 or J3490).
In these situations, it is not appropriate to bill HCPCS code C9399 (unclassified drug or biological), which is for new drugs and biologicals approved by the Food & Drug Administration but a specific HCPCS code has not been assigned yet.
CPT® copyright 2023 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
Subscribe to receive our News, Insights, and Compliance Question of the Week delivered right to your inbox.
Address:Â 5874 Blackshire Path, #13, Inver Grove Heights, MN 55076
Phone:Â (800) 252-1578
Email:Â support@medlearnmedia.com
Hours:Â 9am – 5pm CT
Copyright © 2024 MedLearn Publishing. Powered by MedLearn Media.
Happy World Health Day! Our exclusive webcast, ‘2024 SDoH Update: Navigating Coding and Screening Assessment,’ Â is just $99 for a limited time! Use code WorldHealth24 at checkout.